ES2970887T3 - Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo - Google Patents
Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo Download PDFInfo
- Publication number
- ES2970887T3 ES2970887T3 ES17849432T ES17849432T ES2970887T3 ES 2970887 T3 ES2970887 T3 ES 2970887T3 ES 17849432 T ES17849432 T ES 17849432T ES 17849432 T ES17849432 T ES 17849432T ES 2970887 T3 ES2970887 T3 ES 2970887T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- apc
- amino
- chloropropane
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/08—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383822P | 2016-09-06 | 2016-09-06 | |
| PCT/US2017/050233 WO2018048871A1 (en) | 2016-09-06 | 2017-09-06 | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2970887T3 true ES2970887T3 (es) | 2024-05-31 |
Family
ID=61562003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17849432T Active ES2970887T3 (es) | 2016-09-06 | 2017-09-06 | Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10829443B2 (enExample) |
| EP (2) | EP4364794A3 (enExample) |
| JP (3) | JP7219213B2 (enExample) |
| KR (1) | KR102513800B1 (enExample) |
| CN (2) | CN109996540A (enExample) |
| CA (1) | CA3036071A1 (enExample) |
| DK (1) | DK3509582T3 (enExample) |
| ES (1) | ES2970887T3 (enExample) |
| FI (1) | FI3509582T3 (enExample) |
| MY (1) | MY197630A (enExample) |
| PH (1) | PH12019500493A1 (enExample) |
| SG (1) | SG11201901998WA (enExample) |
| WO (1) | WO2018048871A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| JP7219213B2 (ja) * | 2016-09-06 | 2023-02-07 | ジャズ ファーマスティカルズ アイルランド リミテッド | （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム |
| US11447448B2 (en) | 2018-08-14 | 2022-09-20 | Glenmark Life Sciences Limited | Process for the preparation of solriamfetol and salt thereof |
| AU2020231916B2 (en) | 2019-03-01 | 2025-08-28 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| WO2021001457A1 (en) | 2019-07-04 | 2021-01-07 | Sandoz Ag | Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts |
| IT202000013855A1 (it) * | 2020-06-10 | 2021-12-10 | Flamma Spa | Un processo per la purificazione del (r)-2-ammino-3-fenilpropil carbammato |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| EP4615426A1 (en) * | 2022-11-07 | 2025-09-17 | Axsome Therapeutics | Compositions and methods for treating insomnia |
| EP4642446A2 (en) * | 2022-12-30 | 2025-11-05 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| WO2024194718A1 (en) | 2023-03-22 | 2024-09-26 | Unichem Laboratories Limited | A stable pharmaceutical composition and process for preparing thereof |
| WO2024249560A1 (en) | 2023-05-30 | 2024-12-05 | Axsome Therapeutics, Inc. | Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness |
| WO2025006965A1 (en) | 2023-06-29 | 2025-01-02 | Axsome Therapeutics, Inc. | Methods of administering solriamfetol to lactating women |
| WO2025042959A1 (en) | 2023-08-21 | 2025-02-27 | Axsome Therapeutics, Inc. | Use of solriamfetol for the treatment of orphan diseases |
| WO2025165760A1 (en) * | 2024-01-29 | 2025-08-07 | Axsome Therapeutics, Inc. | Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100197892B1 (ko) * | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| JP4374441B2 (ja) | 1998-12-23 | 2009-12-02 | ジェイピーアイ コマーシャル，リミティド ライアビリティ カンパニー | 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤 |
| RU2202607C2 (ru) * | 2000-03-03 | 2003-04-20 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" | Штамм бактерий methylophilus methylotrophus - продуцент l-фенилаланина (варианты), способ получения l-фенилаланина |
| US20050080268A1 (en) * | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| WO2006050037A1 (en) | 2004-10-28 | 2006-05-11 | Sk Corporation | Adjunctive therapy for depression |
| PL1890684T3 (pl) * | 2005-06-08 | 2014-05-30 | Sk Biopharmaceuticals Co Ltd | Leczenie zaburzeń snu i czuwania |
| ATE459393T1 (de) * | 2005-06-22 | 2010-03-15 | Sk Holdings Co Ltd | Behandlung der sexuellen dysfunktion |
| WO2011005473A2 (en) | 2009-06-22 | 2011-01-13 | Shionogi Pharma, Inc. | Methods for treating or preventing fatigue |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| ES2447295T3 (es) | 2009-11-06 | 2014-03-11 | Sk Biopharmaceuticals Co., Ltd. | Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad |
| RU2557533C2 (ru) | 2009-11-06 | 2015-07-20 | Ск Биофармасъютиклс Ко., Лтд. | Способы лечения синдрома фибромиалгии |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| BR112015022197B1 (pt) | 2013-03-13 | 2022-06-07 | Sk Biopharmaceuticals Co., Ltd. | Uso de um composto para o tratamento de cataplexia |
| US20150018414A1 (en) | 2013-07-12 | 2015-01-15 | Jazz Pharmaceuticals International lll Limited | Promotion of Smoking Cessation |
| CN105873576B (zh) * | 2013-07-18 | 2019-07-19 | 爵士制药国际Iii有限公司 | 治疗肥胖 |
| TWI655179B (zh) | 2014-02-28 | 2019-04-01 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| HK1257569A1 (zh) | 2016-02-16 | 2019-10-25 | The University Of Queensland | 磺醯脲和相关化合物及其用途 |
| JP7219213B2 (ja) * | 2016-09-06 | 2023-02-07 | ジャズ ファーマスティカルズ アイルランド リミテッド | （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム |
| KR101950254B1 (ko) | 2016-09-21 | 2019-02-20 | 유상신 | 차량탑승자의 부재를 감지하는 지능형 카시트 |
| US11447448B2 (en) * | 2018-08-14 | 2022-09-20 | Glenmark Life Sciences Limited | Process for the preparation of solriamfetol and salt thereof |
-
2017
- 2017-09-06 JP JP2019512895A patent/JP7219213B2/ja active Active
- 2017-09-06 FI FIEP17849432.4T patent/FI3509582T3/fi active
- 2017-09-06 DK DK17849432.4T patent/DK3509582T3/da active
- 2017-09-06 US US16/331,069 patent/US10829443B2/en active Active
- 2017-09-06 ES ES17849432T patent/ES2970887T3/es active Active
- 2017-09-06 MY MYPI2019001180A patent/MY197630A/en unknown
- 2017-09-06 WO PCT/US2017/050233 patent/WO2018048871A1/en not_active Ceased
- 2017-09-06 CN CN201780065192.6A patent/CN109996540A/zh active Pending
- 2017-09-06 KR KR1020197011279A patent/KR102513800B1/ko active Active
- 2017-09-06 EP EP23218015.8A patent/EP4364794A3/en active Pending
- 2017-09-06 CA CA3036071A patent/CA3036071A1/en not_active Abandoned
- 2017-09-06 CN CN202510706413.XA patent/CN120574152A/zh active Pending
- 2017-09-06 SG SG11201901998WA patent/SG11201901998WA/en unknown
- 2017-09-06 EP EP17849432.4A patent/EP3509582B1/en active Active
-
2019
- 2019-03-06 PH PH12019500493A patent/PH12019500493A1/en unknown
-
2020
- 2020-11-06 US US17/091,222 patent/US11560354B2/en active Active
-
2021
- 2021-09-24 JP JP2021155292A patent/JP7642506B2/ja active Active
-
2022
- 2022-12-14 US US18/066,000 patent/US12384743B2/en active Active
-
2024
- 2024-09-19 JP JP2024161956A patent/JP2024178291A/ja active Pending
-
2025
- 2025-07-11 US US19/266,767 patent/US20250340509A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019535643A (ja) | 2019-12-12 |
| US20250340509A1 (en) | 2025-11-06 |
| CN109996540A (zh) | 2019-07-09 |
| FI3509582T3 (fi) | 2024-02-08 |
| EP3509582B1 (en) | 2023-12-20 |
| US11560354B2 (en) | 2023-01-24 |
| SG11201901998WA (en) | 2019-04-29 |
| US20230183172A1 (en) | 2023-06-15 |
| JP7219213B2 (ja) | 2023-02-07 |
| EP4364794A2 (en) | 2024-05-08 |
| US20190194126A1 (en) | 2019-06-27 |
| US12384743B2 (en) | 2025-08-12 |
| JP2022003062A (ja) | 2022-01-11 |
| EP4364794A3 (en) | 2024-07-24 |
| PH12019500493A1 (en) | 2019-05-27 |
| EP3509582A4 (en) | 2020-05-13 |
| MY197630A (en) | 2023-06-29 |
| JP2024178291A (ja) | 2024-12-24 |
| CA3036071A1 (en) | 2018-03-15 |
| JP7642506B2 (ja) | 2025-03-10 |
| KR20190065311A (ko) | 2019-06-11 |
| CN120574152A (zh) | 2025-09-02 |
| DK3509582T3 (en) | 2024-02-12 |
| KR102513800B1 (ko) | 2023-03-24 |
| WO2018048871A1 (en) | 2018-03-15 |
| US10829443B2 (en) | 2020-11-10 |
| US20210053912A1 (en) | 2021-02-25 |
| EP3509582A1 (en) | 2019-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2970887T3 (es) | Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo | |
| ES2776395T3 (es) | Forma cristalina de ribósido de nicotinamida | |
| ES2355434T3 (es) | 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina como un compuesto con actividad combinada de reabsorción de serotonina, 5-ht3 y 5-ht1a para el tratamiento del dolor o de síntomas residuales en depresión con relación al sueño y la cognición. | |
| ES2963057T3 (es) | Forma cristalina de ribósido de nicotinamida | |
| JP7366002B2 (ja) | カルバモイルフェニルアラニノール類縁体およびその使用 | |
| RU2624446C2 (ru) | Трициклические соединения, композиции, содержащие указанные соединения, и их применения | |
| ES2896503T3 (es) | Sal de succinato de (+)-alfa dihidrotetrabenazina | |
| ES3001085T3 (es) | Métodos de tratar alteraciones del comportamiento | |
| US20190284239A1 (en) | Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha | |
| JP2020512987A (ja) | 運動障害の治療における使用のためのジヒドロテトラベナジン | |
| ES2587064T3 (es) | Sales fumarato novedosas de un antagonista del receptor de histamina H3 | |
| KR20140111044A (ko) | 구연산아일데나필 결정 형태 o 및 그의 제조방법과 용도 | |
| ES2806739T3 (es) | Composición farmacéutica | |
| ES2566671T3 (es) | Cristal de sal de un compuesto de piridina fusionado | |
| ES2868024T3 (es) | Tetrahidrato de ligando H3, su procedimiento de preparación y composiciones farmacéuticas que lo comprenden | |
| JP2010520236A (ja) | リソフィリンアナログとその使用法 | |
| CN118647618A (zh) | Rabeximod化合物 | |
| RU2699669C1 (ru) | Новые составы N-карбамоилметил-4-фенил-2-пирролидона | |
| HK40009279A (en) | Solvate form of (r)-2-amino-3-phenylpropyl carbamate | |
| RU2696277C2 (ru) | Новый состав N-карбамоилметил-4-фенил-2-пирролидона | |
| CN104370792B (zh) | 奥拉西坦化合物 | |
| TW202425961A (zh) | 一種κ阿片受體激動劑藥物組合物及其製備方法和用途 | |
| WO2023236927A1 (zh) | 4-羰基氨基异吲哚啉-1,3-二酮类化合物及其制备方法、药物组合及用途 | |
| PL244458B1 (pl) | Sól memantyny, sposób jej otrzymywania, kompozycja i zastosowanie |